Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Thomas Müller

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Concepts & Ideas

Activities & Behaviors

Psychomotor Performance

Physiology

Procedures

Geographic Areas

Germany

Anatomy

Brain

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Kofler Sieglinde; Bigdeli Amir K; Kaczmarek Ingo; Kellerer Diana; Müller Thomas; Schmoeckel Michael; Steinbeck Gerhard; Uberfuhr Peter; Reichart Bruno; Meiser Bruno
Long-term outcomes after 1000 heart transplantations in six different eras of innovation in a single center.
Spindler Volker; Heupel Wolfgang-Moritz; Efthymiadis Athina; Schmidt Enno; Eming Rüdiger; Rankl Christian; Hinterdorfer Peter; Müller Thomas; Drenckhahn Detlev; Waschke Jens
Desmocollin 3-mediated binding is crucial for keratinocyte cohesion and is impaired in pemphigus.
Müller Thomas; Muhlack Siegfried
Peripheral COMT inhibition prevents levodopa associated homocysteine increase.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Thomas Müller (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Kofler Sieglinde; Bigdeli Amir K; Kaczmarek Ingo; Kellerer Diana; Müller Thomas; Schmoeckel Michael; Steinbeck Gerhard; Uberfuhr Peter; Reichart Bruno; Meiser Bruno
Long-term outcomes after 1000 heart transplantations in six different eras of innovation in a single center.
Transplant international : official journal of the European Society for Organ Transplantation 2009;22(12):1140-50.
2009: Spindler Volker; Heupel Wolfgang-Moritz; Efthymiadis Athina; Schmidt Enno; Eming Rüdiger; Rankl Christian; Hinterdorfer Peter; Müller Thomas; Drenckhahn Detlev; Waschke Jens
Desmocollin 3-mediated binding is crucial for keratinocyte cohesion and is impaired in pemphigus.
The Journal of biological chemistry 2009;284(44):30556-64.
2009: Müller Thomas; Muhlack Siegfried
Peripheral COMT inhibition prevents levodopa associated homocysteine increase.
Journal of neural transmission (Vienna, Austria : 1996) 2009;116(10):1253-6.
2009: Arlt Matthias; Philipp Alois; Zimmermann Markus; Voelkel Sabine; Amann Matthias; Bein Thomas; Müller Thomas; Foltan Maik; Schmid Christof; Graf Bernhard; Hilker Michael
Emergency use of extracorporeal membrane oxygenation in cardiopulmonary failure.
Artificial organs 2009;33(9):696-703.
2009: Müller Thomas
Role of intraspinal steroid application in patients with multiple sclerosis.
Expert review of neurotherapeutics 2009;9(9):1279-87.
2009: Müller Thomas; Kuhn Wilfried
Homocysteine levels after acute levodopa intake in patients with Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2009;24(9):1339-43.
2009: Müller Thomas; Kuhn Wilfried
Cysteine elevation in levodopa-treated patients with Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2009;24(6):929-32.
2009: Siebig S; Kuhls S; Gather U; Imhoff M; Müller T; Bein T; Trabold B; Bele S; Wrede C E
[Noise in intensive care units. Do the alarms for subspecialties differ]
Der Anaesthesist 2009;58(3):240-2, 244-6.
2009: Bauer Stefan; Müller Thomas; Hamm Svetlana
Pattern recognition by Toll-like receptors.
Advances in experimental medicine and biology 2009;653():15-34.
2009: Willemssen Rita; Müller Thomas; Schwarz Michael; Falkenstein Michael; Beste Christian
Response monitoring in de novo patients with Parkinson's disease.
PloS one 2009;4(3):e4898.
2009: Hellwig Kerstin; Schimrigk Sebastian; Beste Christian; Muller Thomas; Gold Ralf
Increase in relapse rate during assisted reproduction technique in patients with multiple sclerosis.
European neurology 2009;61(2):65-8.
2008: Dunkel Marcel; Latz Andreas; Schumacher Karin; Müller Thomas; Becker Dirk; Hedrich Rainer
Targeting of Vacuolar Membrane Localized Members of the TPK Channel Family.
Molecular plant 2008;1(6):938-49.
2008: Lehle Karla; Philipp Alois; Gleich Otto; Holzamer Andreas; Müller Thomas; Bein Thomas; Schmid Christof
Efficiency in extracorporeal membrane oxygenation-cellular deposits on polymethylpentene membranes increase resistance to blood flow and reduce gas exchange capacity.
ASAIO journal (American Society for Artificial Internal Organs : 1992) 2008;54(6):612-7.
2008: Flörchinger Bernhard; Philipp Alois; Klose Alexander; Hilker Michael; Kobuch Reinhard; Rupprecht Leopold; Keyser Andreas; Pühler Thomas; Hirt Stephan; Wiebe Karsten; Müller Thomas; Langgartner Julia; Lehle Karla; Schmid Christof
Pumpless extracorporeal lung assist: a 10-year institutional experience.
The Annals of thoracic surgery 2008;86(2):410-7; discussion 417.
2008: Wahl Claudia; Kautzmann Sabine; Krebiehl Guido; Strauss Karsten; Woitalla Dirk; Müller Thomas; Bauer Peter; Riess Olaf; Krüger Rejko
A comprehensive genetic study of the proteasomal subunit S6 ATPase in German Parkinson's disease patients.
Journal of neural transmission (Vienna, Austria : 1996) 2008;115(8):1141-8.
2008: Müller Thomas; Woitalla Dirk; Goetze Oliver; Erdmann Christoph
Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2008;23(10):1458-61.
2008: Hellwig K; Brune N; Haghikia A; Müller T; Schimrigk S; Schwödiauer V; Gold R
Reproductive counselling, treatment and course of pregnancy in 73 German MS patients.
Acta neurologica Scandinavica 2008;118(1):24-8.
2008: Müller Thomas
Role of homocysteine in the treatment of Parkinson's disease.
Expert review of neurotherapeutics 2008;8(6):957-67.
2008: Müller Thomas; Muhlack Siegfried
Impact of endurance exercise on levodopa-associated cortisol release and force increase in patients with Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996) 2008;115(6):851-5.
2008: Müller Thomas; Kolf Kira; Ander Lema; Woitalla Dirk; Muhlack Siegfried
Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.
Clinical neuropharmacology 2008;31(3):134-40.
2008: Hellwig Kerstin; Schimrigk Sebastian; Fischer Malte; Haghikia Aiden; Müller Thomas; Chan Andrew; Gold Ralf
Allergic and nonallergic delayed infusion reactions during natalizumab therapy.
Archives of neurology 2008;65(5):656-8.
2008: Müller Thomas; Przuntek Horst; Rieks Meike; Mackowiak Anita
Selegiline reduces cisplatin-induced neuronal death in neuroblastoma cells.
Neurological research 2008;30(4):417-9.
2008: Hellwig Kerstin; Beste Christian; Brune Niels; Haghikia Aiden; Müller Thomas; Schimrigk Sebastian; Gold Ralf
Increased MS relapse rate during assisted reproduction technique.
Journal of neurology 2008;255(4):592-3.
2008: Trenkwalder C; Boesch S; Ceballos-Baumann A; Dressler D; Eggert K; Gasser T; Honig H; Müller T; Reichmann H; Sieb J P; Storch A; Odin P; Poewe W
[Intermittent apomorphine injections as rescue therapy for advanced Parkinson's disease. Consensus statement]
Der Nervenarzt 2008;79(4):475-9.
2008: Goetz Christopher G; Laska Eugene; Hicking Christine; Damier Philippe; Müller Thomas; Nutt John; Warren Olanow C; Rascol Olivier; Russ Hermann
Placebo influences on dyskinesia in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2008;23(5):700-7.
2008: Bein T; Müller T; Weber-Carstens S
[Extracorporeal lung support procedures (ECMO/iLA)]
Pneumologie (Stuttgart, Germany) 2008;62(3):137-42.
2008: Meiler Birgit; Andrich Jürgen; Müller Thomas
Rapid switch from oral antiparkinsonian combination drug therapy to duodenal levodopa infusion.
Movement disorders : official journal of the Movement Disorder Society 2008;23(1):145-6.
2008: Ellrichmann Gisa; Harati Ali; Müller Thomas
Deep brain stimulation improves performance of complex instrumental paradigms.
European neurology 2008;60(1):32-6.
2008: Willemssen R; Müller T; Schwarz M; Hohnsbein J; Falkenstein M
Error processing in patients with Parkinson's disease: the influence of medication state.
Journal of neural transmission (Vienna, Austria : 1996) 2008;115(3):461-8.
2007: Riederer Peter; Gerlach Manfred; Müller Thomas; Reichmann Heinz
Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease.
Parkinsonism & related disorders 2007;13(8):466-79.
2007: Philipp Alois; Müller Thomas; Bein Thomas; Foltan Maik; Schmid Franz-Xaver; Birnbaum Dietrich; Schmid Christof
Inhibition of thrombocyte aggregation during extracorporeal lung assist: a case report.
Perfusion 2007;22(4):293-7.
2007: Müller Thomas; Welnic Jacub; Woitalla Dirk; Muhlack Siegfried
Endurance exercise modulates levodopa induced growth hormone release in patients with Parkinson's disease.
Neuroscience letters 2007;422(2):119-22.
2007: Storch Alexander; Jost Wolfgang H; Vieregge Peter; Spiegel Jörg; Greulich Wolfgang; Durner Joachim; Müller Thomas; Kupsch Andreas; Henningsen Henning; Oertel Wolfgang H; Fuchs Gerd; Kuhn Wilfried; Niklowitz Petra; Koch Rainer; Herting Birgit; Reichmann Heinz;
Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.
Archives of neurology 2007;64(7):938-44.
2007: Ellrichmann G; Russ H; Müller T
[Dyskinesia in Parkinson's disease--major clinical features, aetiology, therapy]
Fortschritte der Neurologie-Psychiatrie 2007;75(7):387-96.
2007: Müller Thomas; Kuhn Wilfried
Neurotoxicity of levodopa: treatment-associated homocysteine increase.
Nature clinical practice. Neurology 2007;3(6):E1.
2007: Müller Thomas; Erdmann Christoph; Muhlack Siegfried; Bremen Dirk; Przuntek Horst; Woitalla Dirk
Entacapone improves complex movement performance in patients with Parkinson's disease.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2007;14(5):424-8.
2007: Müller Thomas
Rivastigmine in the treatment of patients with Alzheimer's disease.
Neuropsychiatric disease and treatment 2007;3(2):211-8.
2007: Andrich Jürgen; Saft Carsten; Ostholt Natalie; Müller Thomas
Assessment of simple movements and progression of Huntington's disease.
Journal of neurology, neurosurgery, and psychiatry 2007;78(4):405-7.
2007: Andrich Jürgen; Saft Carsten; Ostholt Natalie; Müller Thomas
Complex movement behaviour and progression of Huntington's disease.
Neuroscience letters 2007;416(3):272-4.
2007: Müller Thomas; Muhlack Siegfried
Acute levodopa intake and associated cortisol decrease in patients with Parkinson disease.
Clinical neuropharmacology 2007;30(2):101-6.
2007: Müller T; Welnic J; Muhlack S
Acute levodopa administration reduces cortisol release in patients with Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996) 2007;114(3):347-50.
2007: Muhlack Siegfried; Welnic Jacub; Woitalla Dirk; Müller Thomas
Exercise improves efficacy of levodopa in patients with Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2007;22(3):427-30.
2007: Goetz Christopher G; Damier Philippe; Hicking Christine; Laska Eugene; Müller Thomas; Olanow C Warren; Rascol Olivier; Russ Hermann
Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
Movement disorders : official journal of the Movement Disorder Society 2007;22(2):179-86.
2007: Beste Christian; Saft Carsten; Andrich Jürgen; Müller Thomas; Gold Ralf; Falkenstein Michael
Time processing in Huntington's disease: a group-control study.
PloS one 2007;2(12):e1263.
2007: Walitza S; Melfsen S; Herhaus G; Scheuerpflug P; Warnke A; Müller T; Lange K W; Gerlach M
Association of Parkinson's disease with symptoms of attention deficit hyperactivity disorder in childhood.
Journal of neural transmission. Supplementum 2007;(72):311-5.
2007: Müller T; Ander L; Kolf K; Woitalla D; Muhlack S
Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996) 2007;114(11):1457-62.
2007: Müller T; Woitalla D; Russ H; Hock K; Haeger D A
Prevalence and treatment strategies of dyskinesia in patients with Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996) 2007;114(8):1023-6.
2006: Franck T; Krueger R; Woitalla D; Müller T; Engelender S; Riess O
Mutation analysis of the seven in absentia homolog 1 (SIAH1) gene in Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996) 2006;113(12):1903-8.
2006: Hauser Robert A; Russ Hermann; Haeger Doris-Anita; Bruguiere-Fontenille Michel; Müller Thomas; Wenning Gregor K
Patient evaluation of a home diary to assess duration and severity of dyskinesia in Parkinson disease.
Clinical neuropharmacology 2006;29(6):322-30.
2006: Muhlack Siegfried; Lemmer Wimar; Klotz Peter; Müller Thomas; Lehmann Erlo; Klieser Eckhard
Anxiolytic effect of rescue remedy for psychiatric patients: a double-blind, placebo-controlled, randomized trial.
Journal of clinical psychopharmacology 2006;26(5):541-2.
2006: Müller T; Erdmann C; Muhlack S; Bremen D; Przuntek H; Goetze O; Woitalla D
Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996) 2006;113(10):1441-8.
2006: Hellwig Kerstin; Schimrigk Sebastian; Lukas Carsten; Hoffmann Volker; Brune Nils; Przuntek Horst; Müller Thomas
Efficacy of mitoxantrone and intrathecal triamcinolone acetonide treatment in chronic progressive multiple sclerosis patients.
Clinical neuropharmacology 2006;29(5):286-91.
2006: Müller Thomas; Russ Hermann
Levodopa, motor fluctuations and dyskinesia in Parkinson's disease.
Expert opinion on pharmacotherapy 2006;7(13):1715-30.
2006: Woitalla Dirk; Goetze Oliver; Kim Jeong I; Nikodem Alice B; Schmidt Wolfgang E; Przuntek Horst; Müller Thomas
Levodopa availability improves with progression of Parkinson's disease.
Journal of neurology 2006;253(9):1221-6.
2006: Müller Thomas; Fuchs Gerd; Hahne Matthias; Klein Wolfgang; Schwarz Michael
Diagnostic aspects of early Parkinson's disease.
Journal of neurology 2006;253 Suppl 4():IV29-31.
2006: Saft Carsten; Andrich Jürgen; Meisel Nina-Marie; Przuntek Horst; Müller Thomas
Assessment of simple movements reflects impairment in Huntington's disease.
Movement disorders : official journal of the Movement Disorder Society 2006;21(8):1208-12.
2006: Müller Thomas; Kuhn Wilfried
Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients.
European journal of clinical pharmacology 2006;62(6):447-50.
2006: Müller Thomas; Erdmann Christoph; Bremen Dirk; Schmidt Wolfgang E; Muhlack Siegfried; Woitalla Dirk; Goetze Oliver
Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients.
Clinical neuropharmacology 2006;29(2):61-7.
2006: Müller Thomas; Erdmann Christoph; Muhlack Siegfried; Bremen Dirk; Przuntek Horst; Woitalla Dirk
Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels.
Movement disorders : official journal of the Movement Disorder Society 2006;21(3):332-6.
2006: Muhlack S; Przuntek H; Müller T
Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer's disease.
Pharmacopsychiatry 2006;39(1):16-9.
2006: Hoffmann V; Kuhn W; Schimrigk S; Islamova S; Hellwig K; Lukas C; Brune N; Pöhlau D; Przuntek H; Müller T
Repeat intrathecal triamcinolone acetonide application is beneficial in progressive MS patients.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2006;13(1):72-6.
2006: Schlitter A M; Kurz M; Larsen J P; Woitalla D; Müller T; Epplen J T; Dekomien G
Parkin gene variations in late-onset Parkinson's disease: comparison between Norwegian and German cohorts.
Acta neurologica Scandinavica 2006;113(1):9-13.
2006: Müller T; Welnic J; Fuchs G; Baas H; Ebersbach G; Reichmann H
The DONPAD-study--treatment of dementia in patients with Parkinson's disease with donepezil.
Journal of neural transmission. Supplementum 2006;(71):27-30.
2006: Müller Thomas; Dodel Richard; Fritze Jürgen
[Cost and quality aspects in the treatment of Parkinson's disease]
Zeitschrift für ärztliche Fortbildung und Qualitätssicherung 2006;100(4):291-5.
2006: Hellwig Kerstin; Lukas Carsten; Brune Niels; Schimrigk Sebastian; Przuntek Horst; Müller Thomas
Repeat intrathecal triamcinolone acetonide application reduces acute occurring painful dysesthesia in patients with relapsing remitting multiple sclerosis.
TheScientificWorldJournal 2006;6():460-5.
2005: Müller Thomas; Fowler Brian; Kuhn Wilfried
Levodopa intake increases plasma levels of S-adenosylmethionine in treated patients with Parkinson disease.
Clinical neuropharmacology 2005;28(6):274-6.
2005: Müller Thomas; Lang Undine E; Muhlack Siegfried; Welnic Jacub; Hellweg Rainer
Impact of levodopa on reduced nerve growth factor levels in patients with Parkinson disease.
Clinical neuropharmacology 2005;28(5):238-40.
2005: Berg Daniela; Niwar Marc; Maass Sylvia; Zimprich Alexander; Möller J Carsten; Wuellner Ullrich; Schmitz-Hübsch Tanja; Klein Christine; Tan Eng-King; Schöls Ludger; Marsh Laura; Dawson Ted M; Janetzky Bernd; Müller Thomas; Woitalla Dirk; Kostic Vladimir; Pramstaller Peter P; Oertel Wolfgang H; Bauer Peter; Krueger Rejko; Gasser Thomas; Riess Olaf
Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients.
Movement disorders : official journal of the Movement Disorder Society 2005;20(9):1191-4.
2005: Strauss Karsten M; Martins L Miguel; Plun-Favreau Helene; Marx Frank P; Kautzmann Sabine; Berg Daniela; Gasser Thomas; Wszolek Zbginiew; Müller Thomas; Bornemann Antje; Wolburg Hartwig; Downward Julian; Riess Olaf; Schulz Jörg B; Krüger Rejko
Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease.
Human molecular genetics 2005;14(15):2099-111.
2005: Saft C; Andrich J; Müller T; Przuntek H; Stücker M
[Segmental dysfunction of sweating in multiple system atrophy]
Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete 2005;56(8):773-6.
2005: Müller T; Kuhn W; Przuntek H
Efficacy of budipine and placebo in untreated patients with Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996) 2005;112(8):1015-23.
2005: Hansen Wiebke; Saft Carsten; Andrich Jürgen; Müller Thomas; Wieczorek Stefan; Epplen Jörg T; Arning Larissa
Failure to confirm influence of methyltetrahydrofolate reductase (MTHFR) polymorphisms on age at onset of Huntington disease.
Journal of negative results in biomedicine 2005;4():12.
2004: Hellwig Kerstin; Stein Franz Josef; Przuntek Horst; Müller Thomas
Efficacy of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients with spinal symptoms.
BMC neurology 2004;4(1):18.
2004: Müller T; Przuntek H; Krüger R; Mackowiak A
Antiapoptotic effects of budipine.
Journal of neural transmission (Vienna, Austria : 1996) 2004;111(10-11):1365-73.
2004: Hering Robert; Strauss Karsten M; Tao Xiao; Bauer Andreas; Woitalla Dirk; Mietz Eva-Maria; Petrovic Slobodanka; Bauer Peter; Schaible Wilhelm; Müller Thomas; Schöls Ludger; Klein Christine; Berg Daniela; Meyer Philipp T; Schulz Jörg B; Wollnik Bernd; Tong Liang; Krüger Rejko; Riess Olaf
Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7).
Human mutation 2004;24(4):321-9.
2004: Müller Thomas; Hefter Harald; Hueber Roland; Jost Wolfgang H; Leenders Klaus L; Odin Per; Schwarz Johannes
Is levodopa toxic?
Journal of neurology 2004;251 Suppl 6():VI/44-6.
2004: Müller Thomas; Mannel Marcus; Murck Harald; Rahlfs Volker W
Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial.
Psychosomatic medicine 2004;66(4):538-47.
2004: Muhlack Siegfried; Woitalla Dirk; Welnic Jacob; Twiehaus Svenja; Przuntek Horst; Müller Thomas
Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.
Neuroscience letters 2004;363(3):284-7.
2004: Müller Thomas; Renger Kathrin; Kuhn Wilfried
Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration.
Archives of neurology 2004;61(5):657-60.
2004: Müller T; Benz S; Börnke C; Przuntek H
Differential response in choice reaction time following apomorphine based on prior dopaminergic treatment.
Acta neurologica Scandinavica 2004;109(5):348-54.
2004: Hering R; Petrovic S; Mietz E-M; Holzmann C; Berg D; Bauer P; Woitalla D; Müller T; Berger K; Krüger R; Riess O
Extended mutation analysis and association studies of Nurr1 (NR4A2) in Parkinson disease.
Neurology 2004;62(7):1231-2.
2004: Andrich Jürgen; Saft Carsten; Arz Anneliese; Schneider Birgit; Agelink Markus W; Kraus Peter H; Kuhn Wilfried; Müller Thomas
Hyperhomocysteinaemia in treated patients with Huntington's disease homocysteine in HD.
Movement disorders : official journal of the Movement Disorder Society 2004;19(2):226-8.
2004: Przuntek H; Müller Th; Riederer P
Diagnostic staging of Parkinson's disease: conceptual aspects.
Journal of neural transmission (Vienna, Austria : 1996) 2004;111(2):201-16.
2004: Andrich J; Saft C; Gerlach M; Schneider B; Arz A; Kuhn W; Müller Th
Coenzyme Q10 serum levels in Huntington's disease.
Journal of neural transmission. Supplementum 2004;(68):111-6.
2004: Brune N; Andrich J; Gencik M; Saft C; Müller Th; Valentin S; Przuntek H; Epplen J T
Methyltetrahydrofolate reductase polymorphism influences onset of Huntington's disease.
Journal of neural transmission. Supplementum 2004;(68):105-10.
2004: Saft C; Andrich J; Meisel N M; Przuntek H; Müller Th
Congruent deterioration of complex and simple movements in patients with Huntington's disease.
Journal of neural transmission. Supplementum 2004;(68):97-104.
2004: Woitalla D; Müller T; Benz S; Horowski R; Przuntek H
Transdermal lisuride delivery in the treatment of Parkinson's disease.
Journal of neural transmission. Supplementum 2004;(68):89-95.
2004: Müller Th; Benz S; Börnke Ch; Muhlack S; Woitalla D; Przuntek H
Worsened motor test performance following acute apomorphine injection in previously untreated patients with Parkinson's disease.
Journal of neural transmission. Supplementum 2004;(68):79-87.
2004: Schmid G; Suchan B; Rusin J; Daum I; Köster O; Przuntek H; Müller Th; Peters S
Impact of apomorphine on BOLD signal during movement in normals.
Journal of neural transmission. Supplementum 2004;(68):69-78.
2004: Börnke Ch; Schulte T; Przuntek H; Müller Th
Clinical effects of repetitive transcranial magnetic stimulation versus acute levodopa challenge in Parkinson's disease.
Journal of neural transmission. Supplementum 2004;(68):61-7.
2004: Muhlack S; Konietzka S; Woitalla D; Przuntek H; Müller Th
Simple movement sequences better correlate to levodopa plasma levels than complex ones.
Journal of neural transmission. Supplementum 2004;(68):53-60.
2004: Glass A S; Huynh D P; Franck Th; Woitalla D; Müller Th; Pulst S M; Berg D; Krüger R; Riess O
Screening for mutations in synaptotagmin XI in Parkinson's disease.
Journal of neural transmission. Supplementum 2004;(68):21-8.
2004: Woitalla D; Kuhn W; Müller T
MTHFR C677T polymorphism, folic acid and hyperhomocysteinemia in levodopa treated patients with Parkinson's disease.
Journal of neural transmission. Supplementum 2004;(68):15-20.
2004: Müller Thomas; Voss Birgit; Hellwig Kerstin; Josef Stein Franz; Schulte Thorsten; Przuntek Horst
Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic.
CNS drugs 2004;18(2):105-11.
2003: Saft Carsten; Andrich Jürgen; Meisel Nina-Marie; Przuntek Horst; Müller Thomas
Assessment of complex movements reflects dysfunction in Huntington's disease.
Journal of neurology 2003;250(12):1469-74.
2003: Krüger Rejko; Fischer Christian; Schulte Thorsten; Strauss Karsten M; Müller Thomas; Woitalla Dirk; Berg Daniela; Hungs Marcel; Gobbele Rene; Berger Klaus; Epplen Jörg T; Riess Olaf; Schöls Ludger
Mutation analysis of the neurofilament M gene in Parkinson's disease.
Neuroscience letters 2003;351(2):125-9.
2003: Müller Thomas; Meisel Margareta; Russ Herrmann; Przuntek Horst
Motor impairment influences Farnsworth-Munsell 100 Hue test error scores in Parkinson's disease patients.
Journal of the neurological sciences 2003;213(1-2):61-5.
2003: Müller Th
[Statin-induced Parkinson's-syndrome. Reader's letter on the article by J. Finsterer in "Der Nervenarzt" (2003) 74:115-122]
Der Nervenarzt 2003;74(8):726-7.
2003: Saft C; Andrich J; Stücker M; Przuntek H; Müller T
Asymmetric anhidrosis in MSA.
Neurology 2003;61(2):231.
2003: Schulte T; Böhringer S; Schöls L; Müller T; Fischer C; Riess O; Przuntek H; Berger K; Epplen J T; Krüger R
Modulation of disease risk according to a cathepsin D / apolipoprotein E genotype in Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996) 2003;110(7):749-55.
2003: Hoffmann Volker; Schimrigk Sebastian; Islamova Saida; Hellwig Kerstin; Lukas Carsten; Brune Nils; Pöhlau Dieter; Przuntek Horst; Müller Thomas
Efficacy and safety of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients.
Journal of the neurological sciences 2003;211(1-2):81-4.
2003: Müller Th; Benz S; Börnke C; Russ H; Przuntek H
Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996) 2003;110(6):603-9.
2003: Peters Sören; Suchan Boris; Rusin Joanna; Daum Irene; Köster Odo; Przuntek Horst; Müller Thomas; Schmid Gebhard
Apomorphine reduces BOLD signal in fMRI during voluntary movement in Parkinsonian patients.
Neuroreport 2003;14(6):809-12.
2003: Müller Thomas; Fritze Jürgen
Fibrosis associated with dopamine agonist therapy in Parkinson's disease.
Clinical neuropharmacology 2003;26(3):109-11.
2003: Uekermann J; Daum I; Peters S; Wiebel B; Przuntek H; Müller T
Depressed mood and executive dysfunction in early Parkinson's disease.
Acta neurologica Scandinavica 2003;107(5):341-8.
2003: Müller Thomas; Büttner Thomas; Gholipour Ali Farshad; Kuhn Wilfried
Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease.
Neuroscience letters 2003;341(3):201-4.
2003: Müller T; Woitalla D; Kuhn W
Benefit of folic acid supplementation in parkinsonian patients treated with levodopa.
Journal of neurology, neurosurgery, and psychiatry 2003;74(4):549.
2003: Müller Thomas; Kuhn Wilfried; Schulte Thorsten; Przuntek Horst
Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson's disease.
Neuroscience letters 2003;339(1):25-8.
2003: Müller Thomas; Przuntek Horst; Kuhlmann Anita
Loss of color vision during long-term treatment with pramipexole.
Journal of neurology 2003;250(1):101-2.
2003: Müller Thomas; Voss Birgit; Hellwig Kerstin; Przuntek Horst
Treatment benefit correlates with increase of daily drug costs in Parkinson's disease clinics.
NeuroRehabilitation 2003;18(3):271-5.
2002: Müller Thomas
CPI-1189. Centaur.
Current opinion in investigational drugs (London, England : 2000) 2002;3(12):1763-7.
2002: Reimer Jens; Kuhlmann Anita; Müller Thomas
Neuroleptic malignant-like syndrome after rapid switch from bromocriptine to pergolide.
Parkinsonism & related disorders 2002;9(2):115-6.
2002: Riederer P; Gille G; Müller T; Przuntek H; Reichmann H; Riess O; Schwartz A; Schwarz J; Vogt T
Practical importance of neuroprotection in Parkinson's disease.
Journal of neurology 2002;249 Suppl 3():III/53-6.
2002: Müller Thomas
Dopaminergic substitution in Parkinson's disease.
Expert opinion on pharmacotherapy 2002;3(10):1393-403.
2002: Müller Thomas; Benz Sabine; Przuntek Horst
Apomorphine delays simple reaction time in Parkinsonian patients.
Parkinsonism & related disorders 2002;8(5):357-60.
2002: Schulte Thorsten; Schöls Ludger; Müller Thomas; Woitalla Dirk; Berger Klaus; Krüger Rejko
Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson's disease.
Neuroscience letters 2002;326(1):70-2.
2002: Przuntek Horst; Bittkau Stefan; Bliesath Harald; Büttner Ulrich; Fuchs Gerd; Glass Joachim; Haller Harald; Klockgether Thomas; Kraus Peter; Lachenmayer Lutz; Müller Dieter; Müller Thomas; Rathay Bernhard; Sgonina Jörg; Steinijans Volker; Teshmar Elemer; Ulm Gudrun; Volc Dieter
Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen.
Archives of neurology 2002;59(5):803-6.
2002: Müller T; Woitalla D; Peters S; Kohla K; Przuntek H
Progress of visual dysfunction in Parkinson's disease.
Acta neurologica Scandinavica 2002;105(4):256-60.
2002: Müller Thomas
Drug treatment of non-motor symptoms in Parkinson's disease.
Expert opinion on pharmacotherapy 2002;3(4):381-8.
2002: Müller Th; Woitalla D; Fowler B; Kuhn W
3-OMD and homocysteine plasma levels in parkinsonian patients.
Journal of neural transmission (Vienna, Austria : 1996) 2002;109(2):175-9.
2002: Muller Thomas; Benz Sabiene; Przuntek Horst
Tapping and peg insertion after levodopa intake in treated and de novo parkinsonian patients.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2002;29(1):73-7.
2002: Müller T; Benz S
Quantification of the dopaminergic response in Parkinson's disease.
Parkinsonism & related disorders 2002;8(3):181-6.
2001: Müller T; Benz S; Börnke C
Delay of simple reaction time after levodopa intake.
Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 2001;112(11):2133-7.
2001: Krüger R; Schöls L; Müller T; Kuhn W; Woitalla D; Przuntek H; Epplen J T; Riess O
Evaluation of the gamma-synuclein gene in German Parkinson's disease patients.
Neuroscience letters 2001;310(2-3):191-3.
2001: Zimprich A; Grabowski M; Asmus F; Naumann M; Berg D; Bertram M; Scheidtmann K; Kern P; Winkelmann J; Müller-Myhsok B; Riedel L; Bauer M; Müller T; Castro M; Meitinger T; Strom T M; Gasser T
Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome.
Nature genetics 2001;29(1):66-9.
2001: Müller T; Woitalla D; Hauptmann B; Fowler B; Kuhn W
Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease.
Neuroscience letters 2001;308(1):54-6.
2001: Peters S; Eising E G; Przuntek H; Müller T
Vascular Parkinsonism: a case report and review of the literature.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2001;8(3):268-71.
2001: Krüger R; Kuhn W; Leenders K L; Sprengelmeyer R; Müller T; Woitalla D; Portman A T; Maguire R P; Veenma L; Schröder U; Schöls L; Epplen J T; Riess O; Przuntek H
Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers.
Neurology 2001;56(10):1355-62.
2001: Müller T
Non-dopaminergic drug treatment of Parkinson's disease.
Expert opinion on pharmacotherapy 2001;2(4):557-72.
2001: Haussermann P; Kuhn W; Przuntek H; Muller T
Integrity of the blood-cerebrospinal fluid barrier in early Parkinson's disease.
Neuroscience letters 2001;300(3):182-4.
2001: Eising E G; Müller T H; Freudenberg L; Müller S P; Dutschka K; Sonnenschein W; Przuntek H; Bockisch A
SPECT imaging with [123I]-beta-CIT in Parkinsonism: comparison of SPECT images obtained by a single-headed and a three-headed gamma camera.
Nuclear medicine communications 2001;22(2):145-50.
2001: Kuhn W; Hummel T; Woitalla D; Müller T
Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD.
Neurology 2001;56(2):281; author reply 281-2.
2000: Müller T; Benz S; Przuntek H
Choice reaction time after levodopa challenge in parkinsonian patients.
Journal of the neurological sciences 2000;181(1-2):98-103.
2000: Müller T; Schäfer S; Kuhn W; Przuntek H
Correlation between tapping and inserting of pegs in Parkinson's disease.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2000;27(4):311-5.
2000: Reichmann H; Sommer U; Fuchs G; Hefter H; Mark G; Müller T; Thümler R; Ulm G; Vieregge P
Workshop IV: drug treatment guidelines for the long-term management of Parkinson's disease.
Journal of neurology 2000;247 Suppl 4():IV/40-1.
2000: Riederer P; Brücke T; Buhmann C; Müller T; Schwartz A; Storch A; Winner B
Workshop II: "neuroprotection"--the Lugano consensus.
Journal of neurology 2000;247 Suppl 4():IV/36-7.
2000: Krüger R; Menezes-Saecker A M; Schöls L; Kuhn W; Müller T; Woitalla D; Berg D; Berger K; Przuntek H; Epplen J T; Riess O
Genetic analysis of the alpha2-macroglobulin gene in early- and late-onset Parkinson's disease.
Neuroreport 2000;11(11):2439-42.
2000: Wintermeyer P; Krüger R; Kuhn W; Müller T; Woitalla D; Berg D; Becker G; Leroy E; Polymeropoulos M; Berger K; Przuntek H; Schöls L; Epplen J T; Riess O
Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients.
Neuroreport 2000;11(10):2079-82.
2000: Müller T; Woitalla D; Hunsdiek A; Kuhn W
Elevated plasma levels of homocysteine in dystonia.
Acta neurologica Scandinavica 2000;101(6):388-90.
2000: Krüger R; Hardt C; Tschentscher F; Jäckel S; Kuhn W; Müller T; Werner J; Woitalla D; Berg D; Kühnl N; Fuchs G A; Santos E J; Przuntek H; Epplen J T; Schöls L; Riess O
Genetic analysis of immunomodulating factors in sporadic Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996) 2000;107(5):553-62.
2000: Rahbar A; Kempkes M; Müller T; Reich S; Welter F L; Meves S; Przuntek H; Bolt H M; Kuhn W
Glutathione S-transferase polymorphism in Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996) 2000;107(3):331-4.
2000: Müller T; Woitalla D; Schulz D; Peters S; Kuhn W; Przuntek H
Tolcapone increases maximum concentration of levodopa.
Journal of neural transmission (Vienna, Austria : 1996) 2000;107(1):113-9.
2000: Woitalla D; Karwasz R; Müller T; Przuntek H; Kuhn W
The activity of catechol-O-methyltransferase in parkinsonian patients with "on-off fluctuations".
Journal of neural transmission (Vienna, Austria : 1996) 2000;107(1):105-11.
2000: Büttner T; Müller T; Kuhn W
Effects of apomorphine on visual functions in Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996) 2000;107(1):87-94.
2000: Krüger R; Müller T; Riess O
Involvement of alpha-synuclein in Parkinson's disease and other neurodegenerative disorders.
Journal of neural transmission (Vienna, Austria : 1996) 2000;107(1):31-40.
1999: Russ H; Müller T; Woitalla D; Rahbar A; Hahn J; Kuhn W
Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects.
Naunyn-Schmiedeberg's archives of pharmacology 1999;360(6):719-20.
1999: Müller T; Kuhn W; Büttner T; Przuntek H
Colour vision abnormalities and movement time in Parkinson's disease.
European journal of neurology : the official journal of the European Federation of Neurological Societies 1999;6(6):711-5.
1999: Müller T; Eising E; Kuhn W; Büttner T; Coenen H H; Przuntek H
Delayed motor response correlates with striatal degeneration in Parkinson's disease.
Acta neurologica Scandinavica 1999;100(4):227-30.
1999: Müller T; Werne B; Fowler B; Kuhn W
Nigral endothelial dysfunction, homocysteine, and Parkinson's disease.
Lancet 1999;354(9173):126-7.
1999: Büttner T; Lack B; Jäger M; Wünsche W; Kuhn W; Müller T; Przuntek H; Postert T
Serum levels of neuron-specific enolase and s-100 protein after single tonic-clonic seizures.
Journal of neurology 1999;246(6):459-61.
1999: Müller T; Przuntek H; Kuhn W; Baum S S; Rommelspacher H
No increase of synthesis of (R)salsolinol in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1999;14(3):514-5.
1999: Krüger R; Vieira-Saecker A M; Kuhn W; Berg D; Müller T; Kühnl N; Fuchs G A; Storch A; Hungs M; Woitalla D; Przuntek H; Epplen J T; Schöls L; Riess O
Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype.
Annals of neurology 1999;45(5):611-7.
1999: Müller T; Sällström Baum S; Häussermann P; Przuntek H; Rommelspacher H; Kuhn W
R- and S-salsolinol are not increased in cerebrospinal fluid of Parkinsonian patients.
Journal of the neurological sciences 1999;164(2):158-62.
1999: Müller T; Amoiridis G; Kuhn W; Przuntek H
Iron deposits in the subthalamic nuclei in Hallervorden-Spatz disease.
European neurology 1999;42(4):240-1.
1999: Przuntek H; Müller T
Clinical efficacy of budipine in Parkinson's disease.
Journal of neural transmission. Supplementum 1999;56():75-82.
1999: Krüger R; Vieira-Säcker A M; Kuhn W; Müller T; Woitalla D; Schöls L; Przuntek H; Epplen J T; Riess O
Analysis of the parkin deletion in sporadic and familial Parkinson's disease. Short communication.
Journal of neural transmission (Vienna, Austria : 1996) 1999;106(2):159-63.
1999: Büttner T; Kuhn W; Dietz M; Müller T; Postert T; Przuntek H; Welter F L
Impaired visual function in focal idiopathic dystonia.
European neurology 1999;41(2):94-8.
1998: Kuhn W; Roebroek R; Blom H; van Oppenraaij D; Müller T
Hyperhomocysteinaemia in Parkinson's disease.
Journal of neurology 1998;245(12):811-2.
1998: Kuhn W; Roebroek R; Blom H; van Oppenraaij D; Przuntek H; Kretschmer A; Büttner T; Woitalla D; Müller T
Elevated plasma levels of homocysteine in Parkinson's disease.
European neurology 1998;40(4):225-7.
1998: Kuhn W; Woitalla D; Gerlach M; Russ H; Müller T
Tolcapone and neurotoxicity in Parkinson's disease.
Lancet 1998;352(9136):1313-4.
1998: Müller T; Kuhn W; Büttner T; Eising E; Coenen H; Haas M; Przuntek H
Colour vision abnormalities do not correlate with dopaminergic nigrostriatal degeneration in Parkinson's disease.
Journal of neurology 1998;245(10):659-64.
1998: Federlein J; Postert T; Przuntek H; Müller T
Central pontine myelinolysis causes bilateral loss of deep sensitivity and pseudochoreoathetosis.
Journal of neurology, neurosurgery, and psychiatry 1998;65(4):607-8.
1998: Büttner T h; Müller T h; Hellwig K; Meves S; Kuhn W
Antipyretic therapy in acute stroke.
Lancet 1998;352(9129):740.
1998: Müller T; Blum-Degen D; Przuntek H; Kuhn W
Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease.
Acta neurologica Scandinavica 1998;98(2):142-4.
1998: Kuhn W; Müller T; Gerstner A; Winkel R; Goetz M E
Platelet monoamine oxidase B activity in "de novo" and l-dopa treated parkinsonian patients and controls.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1998;25(3):249-51.
1998: Kuhn W; Winkel R; Woitalla D; Meves S; Przuntek H; Müller T
High prevalence of parkinsonism after occupational exposure to lead-sulfate batteries.
Neurology 1998;50(6):1885-6.
1998: Müller T; Kuhn W; Börnke C; Büttner T; Przuntek H
Kleine-Levin syndrome and Parkinsonian symptoms--a case report.
Journal of the neurological sciences 1998;157(2):214-6.
1998: Krüger R; Kuhn W; Müller T; Woitalla D; Graeber M; Kösel S; Przuntek H; Epplen J T; Schöls L; Riess O
Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.
Nature genetics 1998;18(2):106-8.
1998: Büttner T; Hellwig K; Müller T; Kuhn W
Intravenously administered acetylsalicylic acid in combination with low-dose heparin in acute ischemic stroke: a safety analysis.
Clinical neuropharmacology 1998;21(1):48-51.
1998: Müller T; Sällström Baum S; Häussermann P; Woitalla D; Rommelspacher H; Przuntek H; Kuhn W
Plasma levels of R- and S-salsolinol are not increased in "de-novo" Parkinsonian patients.
Journal of neural transmission (Vienna, Austria : 1996) 1998;105(2-3):239-46.
1998: Müller T; Kuhn W; Krüger R; Przuntek H
Selegiline as immunostimulant--a novel mechanism of action?
Journal of neural transmission. Supplementum 1998;52():321-8.
1998: Müller T; Farahati J; Kuhn W; Eising E G; Przuntek H; Reiners C; Coenen H H
[123I]beta-CIT SPECT visualizes dopamine transporter loss in de novo parkinsonian patients.
European neurology 1998;39(1):44-8.
1997: Müller T; Eising E G; Reiners C; Przuntek H; Jacob M; Kuhn W
2-[123I]-iodolisuride SPET visualizes dopaminergic loss in de-novo parkinsonian patients: is it a marker of striatal pre-synaptic degeneration?
Nuclear medicine communications 1997;18(12):1115-21.
1997: Müller T; Kuhn W; Büttner T; Przuntek H
Distorted colour discrimination in Parkinson's disease is related to severity of the disease.
Acta neurologica Scandinavica 1997;96(5):293-6.
1997: Eising E G; Müller T T; Zander C; Kuhn W; Farahati J; Reiners C; Coenen H H
SPECT-evaluation of the monoamine uptake site ligand [123I](1R)-2-beta-carbomethoxy-3-beta-(4-iodophenyl)-tropane ([123I]beta-CIT) in untreated patients with suspicion of Parkinson disease.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research 1997;45(8):448-52.
1997: Kuhn W; Müller T
[Therapy of Parkinson disease. 2: New therapy concepts for treating motor symptoms]
Fortschritte der Neurologie-Psychiatrie 1997;65(8):375-85.
1997: Kuhn W; Müller T
[Therapy of Parkinson disease. 1: Standard therapy of motor and non-motor symptoms]
Fortschritte der Neurologie-Psychiatrie 1997;65(8):361-74.
1997: Müller T; Kuhn W; Przuntek H
[Current therapy of idiopathic Parkinson disease. 2: Recent and alternative therapies]
Fortschritte der Medizin 1997;115(13):37-41.
1997: Müller T; Kuhn W; Przuntek H
[Current therapy of idiopathic Parkinson disease. 1: Diagnosis, therapeutic guidelines, standard pharmacotherapy and physical therapy]
Fortschritte der Medizin 1997;115(13):28, 31-4.
1997: Müller T; Kuhn W; Przuntek H
[Non-motor symptoms of Parkinson disease. Significant impact on quality of life--using possible treatments]
Fortschritte der Medizin 1997;115(14):45-8.
1997: Kuhn W; Müller T; Nastos I; Poehlau D
The neuroimmune hypothesis in Parkinson's disease.
Reviews in the neurosciences 1997;8(1):29-34.
1996: Wilfried K; Müller T; Krüger R; Horst P
Selegiline stimulates biosynthesis of cytokines interleukin-1 beta and interleukin-6.
Neuroreport 1996;7(18):2847-8.
1996: Büttner T; Kuhn W; Müller T; Heinze T; Pühl C; Przuntek H
Chromatic and achromatic visual evoked potentials in Parkinson's disease.
Electroencephalography and clinical neurophysiology 1996;100(5):443-7.
1996: Kuhn W; Müller T; Gerlach M; Sofic E; Fuchs G; Heye N; Prautsch R; Przuntek H
Depression in Parkinson's disease: biogenic amines in CSF of "de novo" patients.
Journal of neural transmission (Vienna, Austria : 1996) 1996;103(12):1441-5.
1996: Kuhn W; Müller T; Grosse H; Rommelspacher H
Elevated levels of harman and norharman in cerebrospinal fluid of parkinsonian patients.
Journal of neural transmission (Vienna, Austria : 1996) 1996;103(12):1435-40.
1996: Büttner T; Kuhn W; Müller T; Welter F L; Federlein J; Heidbrink K; Przuntek H
Visual hallucinosis: the major clinical determinant of distorted chromatic contour perception in Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996) 1996;103(10):1195-204.
1996: Kuhn W; Müller T; Winkel R; Danielczik S; Gerstner A; Häcker R; Mattern C; Przuntek H
Parenteral application of NADH in Parkinson's disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis.
Journal of neural transmission (Vienna, Austria : 1996) 1996;103(10):1187-93.
1996: Kuhn W; Müller T
The clinical potential of Deprenyl in neurologic and psychiatric disorders.
Journal of neural transmission. Supplementum 1996;48():85-93.
1996: Gerlach M; Kuhn W; Müller T; Klotz P; Przuntek H
Sustained-release of levodopa: single dose study of a new formulation.
Journal of neural transmission (Vienna, Austria : 1996) 1996;103(6):717-27.
1996: Kuhn W; Heye N; Müller T; Kraus P; Klotz P; Friedrich B; Welter F L; Przuntek H
The motor performance test series in Parkinson's disease is influenced by depression.
Journal of neural transmission (Vienna, Austria : 1996) 1996;103(3):349-54.
1995: Hulley P; Hartikka J; Abdel'Al S; Engels P; Buerki H R; Wiederhold K H; Müller T; Kelly P; Lowe D; Lübbert H
Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo.
The European journal of neuroscience 1995;7(12):2431-40.
1995: Blum-Degen D; Müller T; Kuhn W; Gerlach M; Przuntek H; Riederer P
Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.
Neuroscience letters 1995;202(1-2):17-20.
1995: Kuhn W; Müller T; Grosse H; Dierks T; Rommelspacher H
Plasma levels of the beta-carbolines harman and norharman in Parkinson's disease.
Acta neurologica Scandinavica 1995;92(6):451-4.
1995: Kuhn W; Müller T; Büttner T; Gerlach M
[Acetylsalicylic acid as free radical scavenger. An argument for increased dosages in acute and preventive therapy of vascular diseases]
Fortschritte der Medizin 1995;113(33):483-4.
1995: Büttner T; Kuhn W; Müller T; Patzold T; Przuntek H
Color vision in Parkinson's disease: missing influence of amantadine sulphate.
Clinical neuropharmacology 1995;18(5):458-63.
1995: Kuhn W; Müller T; Bttner T; Gerlach M
Aspirin as a free radical scavenger: consequences for therapy of cerebrovascular ischemia.
Stroke; a journal of cerebral circulation 1995;26(10):1959-60.
1995: Müller T; Büttner T; Kuhn W; Heinz A; Przuntek H
Palinopsia as sensory epileptic phenomenon.
Acta neurologica Scandinavica 1995;91(6):433-6.
1995: Müller T; Kuhn W; Pöhlau D; Przuntek H
Parkinsonism unmasked by lovastatin.
Annals of neurology 1995;37(5):685-6.
1995: Büttner T; Kuhn W; Müller T; Patzold T; Heidbrink K; Przuntek H
Distorted color discrimination in 'de novo' parkinsonian patients.
Neurology 1995;45(2):386-7.
1995: Müller T; Kuhn W; Quack G; Przuntek H
Intravenous application of amantadine and antiparkinsonian efficacy in Parkinsonian patients.
Journal of neural transmission. Supplementum 1995;46():407-13.
1995: Kuhn W; Müller T; Grosse H; Rommelspacher H
Plasma harman and norharman in Parkinson's disease.
Journal of neural transmission. Supplementum 1995;46():291-5.
1995: Kuhn W; Müller T
Neuroimmune mechanisms in Parkinson's disease.
Journal of neural transmission. Supplementum 1995;46():229-33.
1995: Kuhn W; Müller T
Exogenous stimulation of NGF synthesis by catecholamines and their analogues.
Journal of neural transmission. Supplementum 1995;46():189-92.
1993: Müller T; Kuhn W; Przuntek H
Therapy with central active catechol-O-methyltransferase (COMT)-inhibitors: is addition of monoamine oxidase (MAO)-inhibitors necessary to slow progress of neurodegenerative disorders?
Journal of neural transmission. General section 1993;92(2-3):187-95.
1991: Gavranovic M; Müller T; Sofic E; Bilalbegovic Z
Anticonvulsants combined with nifedipine for epilepsy in adults.
The American journal of psychiatry 1991;148(6):808-9.
1990: Fritze J; Sofic E; Müller T; Pfüller H; Lanczik M; Riederer P
Cholinergic-adrenergic balance: Part 2. Relationship between drug sensitivity and personality.
Psychiatry research 1990;34(3):271-9.
1990: Fritze J; Sofic E; Müller T; Pfüller H; Lanczik M; Riederer P
Cholinergic-adrenergic balance: Part 1. Relationship between central and peripheral sensitivities.
Psychiatry research 1990;34(3):259-70.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Thomas Müller

Research Profile (preview)

Disorders

Chemicals & Drugs

Concepts & Ideas

Activities & Behaviors

Physiology

Procedures

Geographic Areas

Anatomy

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Thomas Müller (preview)

All Publications